These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 35819310)
1. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma. Forero-Torres A; Chandler JC; Iyer SP; Kanate AS; Quinlan M; Hoever P; Izquierdo M; Davis J; Madan S Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1099-1109. PubMed ID: 35819310 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab. Lyons RM; Shtivelband M; Kingsley E; Moezi M; Richards D; Sharman J; Feng X; Cannan M; Fellague-Chebra R; Boyd TE Leuk Lymphoma; 2021 Jun; 62(6):1353-1360. PubMed ID: 33448893 [TBL] [Abstract][Full Text] [Related]
3. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Czuczman MS; Kahanic S; Forero A; Davis G; Munteanu M; Van Den Neste E; Offner F; Bron D; Quick D; Fowler N Ann Hematol; 2015 Apr; 94(4):633-41. PubMed ID: 25630297 [TBL] [Abstract][Full Text] [Related]
4. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study). Rummel MJ; Janssens A; MacDonald D; Keating MM; Zaucha JM; Davis J; Lasher J; Babanrao Pisal C; Izquierdo M; Friedberg JW Br J Haematol; 2021 Jun; 193(6):1123-1133. PubMed ID: 33973233 [TBL] [Abstract][Full Text] [Related]
5. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas. Vannata B; Vanazzi A; Negri M; Liptrott SJ; Bartosek AA; Miani M; Di Sanzo A; Cavalli F; Zucca E; Stathis A Hematol Oncol; 2021 Feb; 39(1):60-65. PubMed ID: 33103778 [TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. Flinn IW; Erter J; Daniel DB; Mace JR; Berdeja JG Oncologist; 2019 Aug; 24(8):1035-e623. PubMed ID: 31073022 [TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan. Ishizawa K; Yokoyama M; Kato H; Yamamoto K; Makita M; Ando K; Ueda Y; Tachikawa Y; Suehiro Y; Kurosawa M; Kameoka Y; Nagai H; Uoshima N; Ishikawa T; Hidaka M; Ito Y; Utsunomiya A; Fukushima K; Ogura M Cancer Chemother Pharmacol; 2022 Jul; 90(1):83-95. PubMed ID: 35796785 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959 [TBL] [Abstract][Full Text] [Related]
10. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K; Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007 [TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022 [TBL] [Abstract][Full Text] [Related]
13. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia. Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914 [TBL] [Abstract][Full Text] [Related]
15. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Munakata W; Tobinai K Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460 [TBL] [Abstract][Full Text] [Related]
16. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211 [TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126 [TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
19. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Maloney DG; Ogura M; Fukuhara N; Davis J; Lasher J; Izquierdo M; Banerjee H; Tobinai K Blood Adv; 2020 Aug; 4(16):3886-3893. PubMed ID: 32810220 [TBL] [Abstract][Full Text] [Related]
20. Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Shotton R; Broadbent R; Alchawaf A; Mohamed MB; Gibb A; Martinez-Calle N; Fox CP; Bishton M; Pender A; Gleeson M; Cunningham D; Davies A; Yadollahi S; Eyre TA; Collins G; Djebbari F; Kassam S; Garland P; Watts E; Osborne W; Townsend W; Pocock R; Ahearne MJ; Miall F; Wang X; Linton KM Blood Adv; 2024 Feb; 8(4):878-888. PubMed ID: 37967358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]